EMA publishes update on effectiveness of COVID-19 vaccines against Omicron variant
The European Medicines Agency (EMA) has published an update on the risks posed by the Omicron variant, and on the protection afforded against it by the available COVID-19 vaccines.
According to EMA, Omicron’s risk is currently estimated to be between a third and half of the risk with the Delta variant. Preliminary data also reveals that the effectiveness of vaccines seems to be lower against Omicron than against other variants. Therefore, EMA concludes that more vaccinated people are likely to develop breakthrough disease due to Omicron.
This notwithstanding, EMA also clarifies that the available COVID-19 vaccines remain effective against severe disease and hospitalisation, and that people who have had a booster dose are be